Salvage Cryotherapy for Radiation-Recurrent Prostate Cancer: Outcomes and Complications by Finley, David S. & Belldegrun, Arie S.
Salvage Cryotherapy for Radiation-Recurrent Prostate
Cancer: Outcomes and Complications
David S. Finley & Arie S. Belldegrun
Published online: 11 March 2011
# The Author(s) 2011. This article is published with open access at Springerlink.com
Abstract Potentially curative salvage options for radio-
recurrent prostate cancer include prostatectomy, brachy-
therapy, high-intensity focused ultrasound, and cryotherapy.
Salvage cryoablation technology, surgical technique,
oncologic outcomes, and complication rates have improved
dramatically over the past few decades, shifting this
treatment modality from investigational status to an
established therapeutic option. In this review, we focus
on the most up-to-date oncologic and functional outcomes,
as well as complications of salvage cryotherapy for radiation-
recurrent prostate cancer.
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Introduction
In the United States alone, about one third of the 200,000
men who are diagnosed with prostate cancer each year will
undergo primary radiotherapy (RT) with external beam or
brachytherapy [1, 2]. Failure rates vary according to the
failure definition, RT modality and dose, duration of
follow-up time, and clinicopathologic characteristics, but
generally average 30%–40% (range: 10%–40%) [3–7].
After RT for prostate cancer, it has been demonstrated
that up to one third of patients with biochemical failure
will have a positive biopsy [8]. Currently, there are four
salvage options with curative intent: radical prostatectomy,
brachytherapy, high-intensity focused ultrasound, and
cryoablation. Each treatment choice has varying oncologic
outcomes, side-effect profiles, and complication rates.
Relative to the most aggressive and definitive approach
of salvage prostatectomy, cryoablation seeks to strike a
balance between cancer control and toxicity.
First-generation cryosurgical systems in the 1960s
utilized liquid nitrogen to create an ice ball, which suffered
from imprecise control and monitoring, resulting in a high
complication rate. Today’s third-generation cryounits have
transitioned to argon/helium–based systems according to
the Joule-Thompson principle to create precisely controlled
isotherms through ultrathin needles. Ultrasound imaging
has coevolved with cryotechnology, now incorporating the
routine use of multitemperature sensing probes, double
freeze–thaw cycles, and urethral warming catheters. Taken
together, these revolutionary technical advances along with
improvements in technique have led to dramatic reductions
in toxicity and more favorable outcomes.
Patient Selection
Cryotherapy has been used for primary whole gland and
focal treatment, salvage whole gland and focal ablation, and
local recurrence after radical prostatectomy [9]. While there
are no standardized criteria for the selection of patients for
salvage cryotherapy, treatment is generally recommended
for men with a rising prostate-specific antigen (PSA)
after RT who have a positive prostate biopsy and
negative metastatic work-up [10, 11]. According to the
2008 American Urological Association (AUA) Best
Practice Consensus Statement, ideal candidates for salvage
cryoablation also should have absence of seminal vesicle
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DOI 10.1007/s11934-011-0182-4invasion, a PSA less than 10 ng/mL (preferably <4 ng/mL),
a PSA doubling time of 16 months or more, and at least
a 10-year life expectancy [12￿, 13, 14]. Because up to
30% of high-risk patients may harbor micrometastatic
disease to the lymph nodes, a lymph node dissection may
be indicated [12￿]. Other factors such as gland volume
larger than 50 to 60 cm
3 or prior transurethral resection
may exclude patients in some cases [12￿]. Although a
history of brachytherapy may complicate needle placement,
it is generally not considered to be a contraindication to
salvage cryosurgical ablation.
Oncologic Outcomes
A rim of PSA-producing periurethral tissue will invariably
remain after salvage cryoablation. As a result of these
remnant cells, a zero PSA (ie, undetectable) is unlikely to
be achieved, and therefore, a post-treatment biopsy may be
the most definitive determination of treatment failure
after salvage cryoablation. Although some authors have
suggested a biopsy for patients with various post–salvage
cryotherapy PSA values or in the setting of a persistently
increasing PSA, we recommend routine biopsy in every
patient (Table 1). However, this practice is unpopular with
patients, has potential complications, and is subject to
sampling error [15]. Thus, at most institutions, this is not a
per protocol routine. Among the few series that have
engaged in this practice, positive biopsy rates after salvage
cryoablation have ranged from 0% to 37% (Table 1).
Among one of the largest series, Chin and colleagues [16￿]
biopsied more than 95% of patients (n=178), detecting
cancer in 16.7% of biopsies.
Absent biopsy information, no standardized definition of
treatment success or failure has been established. Instead, a
variety of PSA-based definitions of failure have been
adopted from radiation oncologists as a surrogate for
treatment efficacy. Whether or not a definition based on
radiobiology instead of cryobiology is valid remains to be
determined with any certainty. The AUA Best Practice
Statement indicated that the presence of persistent disease
on biopsy or a PSAvalue less than 0.5 ng/mL are commonly
used outcome end points. Perhaps the most widely used
definitions of failure are: 1) the American Society for
Therapeutic Radiology and Oncology (ASTRO) definition:
three consecutive increases after the nadir PSA level; 2) the
Phoenix definition: PSA nadir after RT + 2 ng/mL; and, 3)
PSA of 2 or higher above post–salvage cryotherapy nadir.
Previously identified pretreatment prognostic variables that
correlate with salvage cryotherapy failure include serum
PSA level of above 10 ng/mL, a PSA doubling time of
16 months or less, postcryotherapy PSA nadir above
0.1 ng/mL, clinical stage higherthanT3,andbiopsyGleason
score of the local recurrence higher than 9 [14, 17–20].
Recently, a large multi-institutional study comprising a pool
of 450 salvage patients was published by Spiess and
colleagues [21] with the intent to create a pretreatment
nomogram. At a median follow-up of 3.4 years, the overall
rate of biochemical failure was 66% (PSA >0.5 ng/mL).
Significant multivariate predictors of biochemical failure
included serum PSA at diagnosis (1 unit increases in the log-
log of the serum PSA [OR 3.8]) and Gleason score at
diagnosis (Gleason ≥8 [OR 2.9]).
Biochemical failure rates vary not only according to the
definition of failure, but also due to the generation of the
cryounit, cycling parameters, clinicopathologic characteris-
tics, and length of follow-up. Across most definitions,
biochemical failure-free rates vary from 59% to 74% [12￿].
Table 1 lists a more specific breakdown of oncologic
variables and outcomes in recent series. Several papers have
reported on long-term disease-specific survival rates.
Bahn et al. [22] reported a 59% to 69% (0.5 ng/mL
definition and 1.0 ng/mL, respectively) biochemical
disease-free survival over a median follow-up of 6.9 years.
Most failures occurred before 3 years, and late failures
beyond 48 months were not observed during the study
follow-up. Cheetham and colleagues [23] provided survival
data for 51 patients who underwent salvage treatment,
reporting prostate cancer death in 8 of 51 (15.7%) patients
at a median time of 6.8 years after cryoablation. Williams et
al. [16￿] reported an 87% 10-year overall survival rate in
men undergoing salvage cryoablation; the disease-specific
survival and disease-free survival were 64% and 39%,
respectively. In terms of prognostic factors, they found a
PSA nadir above 1.0 ng/mL was significantly associated
with poor prognosis.
A major concern with the use of less aggressive tissue-
preserving (eg, urethra) strategies is incomplete treatment
of cancerous foci in remnant locations. A report that may
temper enthusiasm for salvage ablative therapy was
published from Huang and colleagues [24], who documented
the distribution of cancerous foci on whole mount sectioning
after salvage radical prostatectomy. Among 46 patients
with a median post-RT PSA of 4.3 (94% ≤ cT2, and 68%
Gleason 6 to 7), extracapsular extension was present in
43% and seminal vesicle invasion (SVI) in 28%.
Periurethral tumors were noted in 67% of cases, with
7% of tumors in direct contact with the urethra. An
additional 17.4% of tumors were located within 2 mm of
the urethra. Geographically, the apex contained cancer in
93% of cases. This information is sobering for the
cryosurgeon who relies on the thermoprotection of the
urethral warming catheter and apical thermocouples to
balance the challenge of complete treatment of the apex
with the risk of cryoinjury to the urethral sphincter. One
must keep in mind that critical temperatures of −20°C
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Curr Urol Rep (2011) 12:209–215 211are not achieved at the perimeter of the iceball [11]. If
failure after salvage prostatectomy is chiefly due to
micrometastatic disease, the higher failure rates after
salvage ablative therapy must also include SVI and
residual foci of cancer outside the iceball’s “kill zone.”
In addition, there is some evidence that hormone-resistant
prostate cancer cells are more resistant to cryo-induced
cell death, questioning the frequent use of prolonged
androgen deprivation therapy before cryotherapy [25].
Multiparametric endorectal magnetic resonance imaging
(MRI), ultrasound technology, and molecular imaging
continue to improve their discriminatory power to map
the precise anatomic location of tumors. Concurrently,
biopsy technique is becoming less user-dependent with
technologies including MRI/ultrasound fusion [26￿]a n d
the Artemis device (Eigen Corporation, Grass Valley, CA).
The net result of these technological advancements is
enhanced patient selection and increased accuracy for
salvage ablative treatment.
While whole-gland salvage cryoablation is the standard
treatment template, some centers are exploring the use of
partial salvage cryoablation (ie, hemiablation, focal ablation)
in an effort to minimize complication rates, [27]. Eisenberg
and Shinohara achieved 3-year biochemical recurrence–free
survival rates of 89% (ASTRO) and 79% (Phoenix) for
patients undergoing salvage hemi-ablation. On 12-month
follow-up biopsy, 1 of 10 patients had residual disease,
notably in the contralateral lobe and seminal vesicle.
Extreme caution must be exercised given the presence
of occult multifocality. In addition, in this series, three
patients went on to develop metastatic disease. Although
clearly investigational at this time, in highly selected
patients (eg, unilateral, low-volume, low-grade disease)
unwilling to undergo more definitive treatment, focal
salvage ablation may be a guarded option.
Functional Outcomes
Unfortunately, most cryoablation studies lump functional
outcomes along with complications rather than reporting
objective validated instrument-based health-related quality
of life (HRQOL) information obtained at baseline and
long-term follow-up. Ideally, urologists should establish
baseline, short-term, and long-term urinary, sexual, and
bowel function utilizing patient-reported questionnaires
such as the International Prostate Symptom Score and
Sexual Health Inventory for Men. However, in practice,
these instruments are underutilized and data are sparse.
Abdelhady and colleagues [28￿] published, in abstract
form, a HRQOL survey based on the Expanded Prostate
Cancer Index Composite questionnaire after salvage
cryosurgery in 155 men. While no baseline information was
reported, among the 68% of men who responded, the average
post-treatment AUA symptom score was 11.1 (moderate
symptoms), with adequate satisfaction among respondents.
In a prospective study of patients undergoing salvage
cryoablation, Robinson and colleagues [29] followed men
at regular intervals to 24 months after treatment. Based on
the European Organization for Research and Treatment of
Cancer QLQ-C30 and UCLA (University of California,
Los Angeles) Prostate Cancer Index instruments, both
sexual and urinary bother significantly increased between
baseline (35.6% and 0%, respectively) and 24-month
follow-up (51.9% and 29%, respectively).
Urinary Function
Although now over a decade old, in perhaps the largest
HRQOL study among salvage cryotherapy patients, 72% of
men reported some degree of dribbling or leakage at a mean
follow-up of 16.7 months [30]. In addition, 66% of men
reported moderate to severe voiding symptoms. Nguyen
and colleagues [13] found a weighted average incontinence
rate of 36% among salvage studies performed between
1990 and 2002; however, definitions of incontinence
were heterogeneous and not all series included the use of
urethral warming catheters. The weighted average for the
more up-to-date series listed in Table 2 is about 21.7% across
multiple definitions of incontinence (eg, any leakage, ≥ 1
pad) and time frames.
Levy [31] recently reported a correlation between
thermocouple temperatures and voiding function after
prostate cryoablation. In this retrospective series of 58
patients, 10 patients had a history of prior RT. Overall,
37.9% of patients had “altered voiding function” consisting
of a significant change in voiding pattern (eg, urgency,
frequency, postvoid residual). Among patients with a
mean external sphincter temperature less than 23°C, 55%
suffered from altered voiding compared with 25% of
patients who achieved nadir sphincteric temperatures
above this threshold. However, on multivariate analysis,
an external sphincter temperature of 23°C or less was
significantly associated with altered voiding function
(OR 6.26; P=0.012). Among salvage patients, 50%
experienced abnormal voiding, although this was not
statistically significant due to small sample size.
Patients undergoing salvage cryoablation tend to have a
significantly higher complication rate compared with men
undergoing primary treatment due to the retreatment of
irradiated, poorly vascularized, anatomically altered tissue
[30, 32, 33]. Yin et al. [34] utilized SEER (Surveillance,
Epidemiology, and End Results)-Medicare–linked data
among patients who had undergone salvage cryotherapy,
reporting a 30% prevalence of an incontinence diagnosis
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Curr Urol Rep (2011) 12:209–215 213compared with 25.0% of men undergoing primary
cryotherapy. In another series that included primary and
salvage groups, Anastasiadis and colleagues [35]r e p o r t e d
incontinence rates of 5.9% and 10%, respectively, and
erectile dysfunction rates of 86% and 90%, respectively.
Thus, while the salvage patients generally tend to have
higher complication rates and worse functional outcomes,
the magnitude of the difference is much less in modern
series.
Erectile Function
Baseline erectile dysfunction rates are high after RT at study
entry for most cryoablation series, especially in light of
possible hormonal use, ranging from about 60% to 80%
(Table 2). In addition, the use of phosphodiesterase-5
inhibitors and injection therapy often are unclear in many
reports. However, some general trends can be extracted from
the literature. Utilizing validated questionnaires, Perotte and
colleagues [30] found, among the 41% of prepotent men
before salvage cryotherapy, only 15.2% were able to achieve
penetration after treatment; an additional 23.9% of men had
partial erections. Ismail et al. [36]f o u n d6o f1 4( 4 2 . 9 % )
prepotent men retained their baseline function. Yin et al. [34]
reported a 44% prevalence of an erectile dysfunction
diagnosis compared with 38.2% of men undergoing primary
cryotherapy. Whether or not the continuous administration of
phosphodiesterase-5 inhibitors improves erectile function
following salvage cryoablation awaits prospective random-
ized data.
Complications
Historically, with first-generation liquid nitrogen–based
systems, lack of urethral warmers, and thermocouples, the
most feared complications such as rectal fistula, urethral
sloughing, and urinary incontinence were encountered at an
unacceptable rate. Today, with third-generation cryounits,
smaller probes with variable isotherm contours, advanced
imaging, multitemperature thermocouples to precisely
monitor temperatures near critical structures, and urethral
warmers, complication rates have improved dramatically. In
the salvage setting, regardless of the treatment modality, the
observed complication rates are higher than for primary
treatment [12￿, 13, 17, 30]. However, overall contempo-
rary complication rates for salvage cryoablation have
trended down to reasonable levels. Particularly for the
older comorbid patient who is not an ideal candidate for
mainstay salvage prostatectomy, cryoablation may be an
acceptableoption.Themostprevalentcomplicationsarelisted
in Table 2.
Conclusions
Tremendous technological inroads have led to the firm
establishment of salvage cryosurgery as a viable treatment
option with curative intent for radio-recurrent prostate
cancer. Durable biochemical relapse–free rates range
from 34% to 68% depending on the definition. Compli-
cation rates have trended down with advances in
technique and technology. Standardized, protocol-based,
clinical trials are needed.
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